Work

Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Year: 2021

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)01499-3

Authors: Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Sumeet Ambarkhane, Georg Hess, Gilles Salles

Institutions: Mayo Clinic, Asan Medical Center, Memorial Sloan Kettering Cancer Center, University of Alberta, Hôpital Maisonneuve-Rosemont, Université de Montréal, Paracelsus Medical University, The University of Melbourne, St Vincent's Hospital Melbourne, University Medical Center Freiburg, University of Utah, University of Bologna, The University of Sydney, Concord Repatriation General Hospital, MorphoSys (Germany), Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200010256

FWCI: 0.287

Cites:

Cited by: 2

Related to: 10